THE UNIVERSITY OF LIVERPOOL

Their core work

The University of Liverpool is a major UK research university with deep strengths in drug discovery, particle physics, infectious disease, and life sciences. Their H2020 portfolio reveals a university that bridges fundamental science — from neutrino oscillations to Drosophila genetics — with translational health research in pharmacogenomics, cancer monitoring, and antimicrobial resistance. They are heavily involved in Marie Skłodowska-Curie researcher training and mobility programmes, making them a key node for developing early-career researchers across Europe. Their work spans from characterizing nanomedicines and developing animal vaccines to building next-generation particle accelerator infrastructure.

What they specialise in

How they've shifted over time

In the early H2020 period (2014–2018), Liverpool's portfolio was broadly distributed across environmental and ecosystem science (freshwater, coastal, marine biodiversity), public health, and research infrastructure — reflecting a generalist research university engaging widely. By 2019–2022, a clear sharpening occurred toward drug discovery (drug targets, solute carriers, transporters), cancer clinical research (rectal cancer, active monitoring, imaging), and fundamental physics (neutrino oscillations, catalysis). This shift suggests the university consolidated around areas where it has critical mass and competitive advantage, moving from broad participation toward deeper specialization in translational medicine and physical sciences.

Liverpool is concentrating its European research around translational drug discovery and precision oncology — expect future proposals in AI-driven drug target identification and clinical decision support.

How they like to work

Liverpool operates primarily as an active partner (101 of 148 projects), but coordinates a meaningful share (42 projects, ~28%), indicating they can both lead and contribute. With 1,356 unique partners across 75 countries, they function as a broad hub rather than a loyal-partner institution — they build new connections readily. The heavy MSCA involvement (34 projects across RISE, ITN, and Individual Fellowships) signals an organization that invests heavily in researcher exchange, making them an excellent partner for training-oriented consortia.

With 1,356 unique consortium partners spanning 75 countries, Liverpool has one of the most extensive collaboration networks among UK universities in H2020. Their reach is genuinely global, though the density of partnerships is strongest across Western Europe, with significant connections to the US and Japan through accelerator science programmes.

What sets them apart

Liverpool stands out for its unusual combination of world-class particle physics infrastructure expertise and strong translational biomedical research — few universities bridge these two domains at this scale in H2020. Their 28% coordination rate is notably high for a UK university of their size, showing genuine project leadership capacity rather than passive participation. The concentration of MSCA projects (34 total) makes them one of the top UK destinations for researcher mobility, valuable for any consortium needing a training or knowledge-exchange component.

Highlights from their portfolio

• ENERCAPSULE
  Largest coordinated project (€2M over 7 years) on nanoencapsulation for energy storage — shows materials science leadership and long-term commitment.
• EVOLHGT
  ERC-funded project (€1.5M, coordinator) on horizontal gene transfer barriers — demonstrates ability to win prestigious individual excellence grants.
• U-PGx
  Major pharmacogenomics initiative (€1M contribution) making genetic data actionable for treatment decisions — exemplifies their translational medicine strength.